Small Cell Lung Cancer (SCLC)Symptoms, Doctors, Treatments, Advances & More
Small Cell Lung Cancer (SCLC) Overview
Learn About Small Cell Lung Cancer (SCLC)
View Main Condition: Lung Cancer
Duke Cancer Center
Thomas Stinchcombe is an Oncologist and a Hematologist Oncology provider practicing medicine in Durham, North Carolina. Dr. Stinchcombe is rated as an Elite provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery. Dr. Stinchcombe is board certified in American Board Of Internal Med, Medical Oncology. Dr. Stinchcombe is currently accepting new patients.
Fox Chase Cancer Center
Hossein Borghaei is an Oncologist and a Radiologist practicing medicine in Philadelphia, Pennsylvania. Dr. Borghaei is rated as an Elite provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Borghaei is board certified in American Board Of Internal Medicine - Medical Oncology.
Ravi Salgia, M.D., PH.D.
Ravi Salgia is an Oncologist practicing medicine in Duarte, California. Dr. Salgia is rated as an Elite provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Gastrostomy.
Summary: This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.
Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. One of these drugs (atezolizumab) is approved to treat certain cancers. Researchers want to find out if lower doses of this drug might provide the same benefit with fewer adverse effec...
